# GNLX catalysts: GENELUX Corp PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/gnlx/catalysts

> GENELUX Corp (GNLX) has 4 upcoming catalysts. The next is the olvimulogene nanivacirepvec primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | GENELUX Corp |
| Ticker | GNLX (Nasdaq) |
| SEC CIK | 1231457 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/gnlx |

## Cash runway

Cash $18.7M as of 2026-06-30; quarterly burn $6.4M; about 8.7 months of runway at that rate (XBRL company facts, accession 0001493152-26-037667).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2024 | [VIRO-25 trial start](https://sec-api.dev/pdufa/viro-25) | GNLX | recurrent NSCLC | completed | "Newsoara is generally obligated under our license agreement with Newsoara, dated September 27, 2021 (the "Newsoara License Agreement") to fund a Phase 2, open-label, randomized, and controlled clinical trial designed to evaluate the efficacy and safety of intravenously delivered Olvi-Vec oncolytic VACV for patients with recurrent NSCLC in the United States, which VIRO-25 trial is now ongoing with the first patient dosed in October 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1231457/000164117225008838/form10-q.htm)) |
| 2H 2025 | [VIRO-25 interim data readout](https://sec-api.dev/pdufa/viro-25) | GNLX |  | scheduled | "We expect to report interim results from the NSCLC trial in the second half of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1231457/000164117225001184/form10-k.htm)) |
| 2H 2025 | [VIRO-25 topline data readout](https://sec-api.dev/pdufa/viro-25) | GNLX |  | scheduled | "For the Company's Phase 2 VIRO-25 trial in the United States, the Company anticipates reporting a readout of interim results in the second half of 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1231457/000164117225000528/form8-k.htm)) |
| 1H 2026 | [GENELUX Corp topline data readout](https://sec-api.dev/companies/gnlx/catalysts) | GNLX |  | scheduled | "Company anticipates reporting topline results from the Phase 3 trial in the first half of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1231457/000164117225000528/form8-k.htm)) |
| 1H 2026 | [GENELUX Corp topline data readout](https://sec-api.dev/companies/gnlx/catalysts) | GNLX |  | scheduled | "3 trial with topline results anticipated in the first half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1231457/000164117225008838/form10-q.htm)) |
| 2026 | [GOG-3076 topline data readout](https://sec-api.dev/pdufa/gog-3076) | GNLX |  | scheduled | "Additional systemic lung cancer data expected throughout 2026, alongside topline data from Phase 3 ovarian cancer trial (OnPrime/GOG-3076)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1231457/000149315226000270/ex99-1.htm)) |
| 2H 2026 | [MVASI® (bevacizumab) topline data readout](https://sec-api.dev/pdufa/bevacizumab) | GNLX |  | scheduled | "We anticipate reporting topline results in the second half of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/form10-k.htm)) |
| December 2026 | [Olvimulogene nanivacirepvec primary completion](https://sec-api.dev/pdufa/olvimulogene-nanivacirepvec) | GNLX |  | scheduled | "NCT05281471 (Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Genelux Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05281471)) |
| Dec 2026 to Mar 2027 | [Olvimulogene nanivacirepvec topline data readout](https://sec-api.dev/pdufa/olvimulogene-nanivacirepvec) | GNLX |  | scheduled | "NCT05281471 (Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Genelux Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05281471)) |
| February 2027 | [Olvimulogene nanivacirepvec primary completion](https://sec-api.dev/pdufa/olvimulogene-nanivacirepvec) | GNLX |  | scheduled | "NCT06463665 (Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Genelux Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06463665)) |
| Feb to May 2027 | [Olvimulogene nanivacirepvec topline data readout](https://sec-api.dev/pdufa/olvimulogene-nanivacirepvec) | GNLX |  | scheduled | "NCT06463665 (Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Genelux Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06463665)) |

## Drugs

- [GOG-3076](https://sec-api.dev/pdufa/gog-3076): 
- [Olvimulogene nanivacirepvec](https://sec-api.dev/pdufa/olvimulogene-nanivacirepvec): Advanced Non-squamous Non-small-cell Lung Cancer, Platinum-resistant Ovarian Cancer
- [VIRO-25](https://sec-api.dev/pdufa/viro-25): recurrent nsclc

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/gnlx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GNLX catalysts: GENELUX Corp PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/gnlx/catalysts

```bibtex
@misc{secapidev_companies_gnlx_catalysts_20261116,
  title        = {GNLX catalysts: GENELUX Corp PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/gnlx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_gnlx_catalysts_20261116","title":"GNLX catalysts: GENELUX Corp PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/gnlx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
